doi: 10.2147/ndt.s1450.
Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents
Affiliations
- PMID: 19043516
- PMCID: PMC2536539
- DOI: 10.2147/ndt.s1450
Item in Clipboard
Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents
Neuropsychiatr Dis Treat.
2008 Aug.
Abstract
This is a review of the clinical trials investigating the efficacy and safety of risperidone in the treatment of children with autistic spectrum disorders (ASD). The main clinical characteristics are impairment in social skills, communication difficulties, repetitive movements and behaviors, including stereotypies. Pharmacotherapy is mainly directed at the so-called target symptoms, ie, behavioral disorders and the various kinds of repetitions associated with ASD. According to the available data, risperidone seems to be moderately efficacious and safe for treating behavioral disorders. 4 double blind controlled trial. 3 reanalysis studies, and 12 open studies have documented the role of risperidone in children with ASD. Controlled studies have been thoroughly considered in this review.
Keywords: autism; pervasive developmental disorders; risperidone.
Similar articles
-
Role of risperidone in children with autism spectrum disorder.Ann Pharmacother. 2006 May;40(5):909-16. doi: 10.1345/aph.1G389. Epub 2006 Mar 7. Ann Pharmacother. 2006. PMID: 16684811 Review.
-
The Effects of Risperidone on Cognition in People With Autism Spectrum Disorder: A Systematic Review.Cureus. 2023 Sep 19;15(9):e45524. doi: 10.7759/cureus.45524. eCollection 2023 Sep. Cureus. 2023. PMID: 37731686 Free PMC article. Review.
-
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.Pediatrics. 2004 Nov;114(5):e634-41. doi: 10.1542/peds.2003-0264-F. Epub 2004 Oct 18. Pediatrics. 2004. PMID: 15492353 Clinical Trial.
-
Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):685-93. doi: 10.1097/00004583-199705000-00020. J Am Acad Child Adolesc Psychiatry. 1997. PMID: 9136504 Clinical Trial.
-
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.Arch Gen Psychiatry. 1998 Jul;55(7):633-41. doi: 10.1001/archpsyc.55.7.633. Arch Gen Psychiatry. 1998. PMID: 9672054 Clinical Trial.
Cited by
-
Autism spectrum disorders.Ann Saudi Med. 2010 Jul-Aug;30(4):295-300. doi: 10.4103/0256-4947.65261. Ann Saudi Med. 2010. PMID: 20622347 Free PMC article. Review.
-
Drosophila Ube3a regulates monoamine synthesis by increasing GTP cyclohydrolase I activity via a non-ubiquitin ligase mechanism.Neurobiol Dis. 2011 Mar;41(3):669-77. doi: 10.1016/j.nbd.2010.12.001. Epub 2010 Dec 13. Neurobiol Dis. 2011. PMID: 21147225 Free PMC article.
-
Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.Trends Psychiatry Psychother. 2022 Jun 13;44:e20200149. doi: 10.47626/2237-6089-2020-0149. Trends Psychiatry Psychother. 2022. PMID: 34043900 Free PMC article.
-
A randomised controlled trial of bumetanide in the treatment of autism in children.Transl Psychiatry. 2012 Dec 11;2(12):e202. doi: 10.1038/tp.2012.124. Transl Psychiatry. 2012. PMID: 23233021 Free PMC article. Clinical Trial.
-
Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications.Front Pharmacol. 2024 Feb 5;14:1285967. doi: 10.3389/fphar.2023.1285967. eCollection 2023. Front Pharmacol. 2024. PMID: 38375208 Free PMC article. Review.
References
-
- Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry. 2007;61:545–50. - PubMed
-
- Aman MG. Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol. 2004;11:225–8. - PubMed
-
- Aman MG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89:485–91. - PubMed
-
- Aman MG, Tassé MJ, Rojahn J, et al. The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17:41–57. - PubMed
-
- [APA] American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders. 4. Washington, DC: American Psychiatric Association; 1994. Pervasive developmental disorders.
LinkOut - more resources
Full Text Sources
Other Literature Sources
